Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind multicenter study of long-acting octreotide injection in acromegaly
CTR20240175Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of octreotide in acromegaly, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Apr 2024; status: active.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on CTR20240175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240175.